Score Overview
Explore the 2021 public Archive ranking →
Where Pfizer Inc has ranked, year by year
Showing all available years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- PFE
1996: 29.9% · 2021: 15.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 28.72 | — |
1 Year2025-09-26 | $ 22.20 | 29.35% |
5 Years2021-09-28 | $ 33.03 | -13.06% |
10 Years2016-09-28 | $ 20.47 | 40.28% |
20 Years2006-09-28 | $ 11.22 | 156.06% |
30 Years1996-09-27 | $ 4.38 | 6x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 |
|---|---|---|---|---|---|---|
| Price | $ 28.72 | $ 22.20 | $ 33.03 | $ 20.47 | $ 11.22 | $ 4.38 |
| Return | — | 29.35% | -13.06% | 40.28% | 156.06% | 6x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 63.69B | $ 4.33B | $ 11.69B |
| 2025 | $ 62.57B | $ 7.77B | $ 13.59B |
| 2024 | $ 63.62B | $ 8.02B | $ 20.47B |
| 2023 | $ 59.55B | $ 2.13B | $ 12.69B |
| 2022 | $ 100.33B | $ 31.36B | $ 22.73B |
| 2021 | $ 81.28B | $ 22.14B | $ 31.06B |
| 2020 | $ 41.65B | $ 9.15B | $ 12.22B |
| 2019 | $ 41.17B | $ 16.27B | $ 9.83B |
| 2018 | $ 53.64B | $ 11.15B | $ 18.83B |
| 2017 | $ 52.54B | $ 21.30B | $ 19.99B |
| 2016 | $ 52.82B | $ 7.21B | $ 17.85B |
| 2015 | $ 48.85B | $ 6.96B | $ 23.29B |
| 2014 | $ 49.60B | $ 9.08B | $ 36.12B |
| 2013 | $ 51.58B | $ 11.64B | $ 32.40B |
| 2012 | $ 54.65B | $ 9.78B | $ 32.39B |
| 2011 | $ 61.03B | $ 8.70B | $ 26.45B |
| 2010 | $ 67.05B | $ 8.26B | $ 28.01B |
| 2009 | $ 50.00B | $ 8.63B | $ 25.96B |
| 2008 | $ 48.29B | $ 8.02B | $ 23.73B |
| 2007 | $ 48.42B | $ 8.21B | $ 25.47B |
| 2006 | $ 48.37B | $ 11.02B | $ 27.71B |
| 2005 | $ 47.40B | $ 7.61B | $ 22.22B |
| 2004 | $ 52.51B | $ 11.33B | $ 19.89B |
| 2003 | $ 45.18B | $ 3.91B | $ 11.95B |
| 2002 | $ 32.37B | $ 9.12B | $ 12.55B |
| 2001 | $ 32.25B | $ 7.78B | $ 8.61B |
| 2000 | $ 29.57B | $ 3.72B | $ 6.86B |
| 1999 | $ 16.20B | $ 3.17B | $ 6.38B |
| 1998 | $ 13.54B | $ 3.35B | $ 1.55B |
| 1997 | $ 12.50B | $ 2.21B | $ 877M |
| 1996 | $ 11.30B | $ 1.92B | $ 1.15B |
| 1995 | $ 10.02B | $ 1.57B | $ 403M |
| 1994 | $ 8.28B | $ 1.29B | $ 1.45B |
| 1993 | $ 7.47B | $ 657M | $ 729M |
| 1992 | $ 7.23B | $ 810M | $ 1.25B |
| 1991 | $ 6.95B | $ 722M | $ 1.31B |
| 1990 | $ 6.40B | $ 801M | $ 870M |
| 1989 | $ 5.67B | $ 681M | $ 825M |
| 1988 | $ 5.38B | $ 791M | $ 807M |
| 1987 | $ 4.91B | $ 690M | $ 1.03B |
| 1986 | $ 4.47B | $ 660M | $ 398M |
| 1985 | $ 4.02B | $ 579M | $ 412M |
Pfizer Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 41.65B to $ 62.57B and net income declined from $ 9.15B to $ 7.77B. Revenue increased in 3 of those 5 years; net income in 2.
Across Pfizer Inc's full reported history, from 1985 to 2025, revenue grew from $ 4.02B to $ 62.57B and net income grew from $ 579M to $ 7.77B. Revenue increased in 73% of the years measured; net income in 61%.
Pfizer Inc currently holds a 20-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.
Membership
Continue PFE’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
